SEC Form 4 · accession 0001437749-26-029963
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Drew Smith
Officer — General Counsel
Period of report
Sep 7, 2026
Accepted (ET)
Sep 9, 2026 · 2:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Sep 7, 2026 | M | 3,334 | — | A | 54,660 | D | |
| Ordinary SharesF2 | Sep 8, 2026 | S | 1,519 | $42.54 | D | 53,141 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Sep 7, 2026 | M | 3,334 | D | — | — | Ordinary Shares | 3,334 | 0 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- F2Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- F3The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.